Capital Management Associates (New York)’s iShares Biotechnology ETF IBB Stock Holding History

Capital Management Associates (New York)’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$675K	Hold	4,000	–	–	1.12%	34
2025 Q4	$675K	Buy	+4,000	New	+$650K	0.99%	38
2022 Q1	–	Sell	-9,600	Closed	-$1.47M	–	84
2021 Q4	$1.47M	Hold	9,600	–	–	1.43%	24
2021 Q3	$1.55M	Hold	9,600	–	–	1.53%	17
2021 Q2	$1.57M	Hold	9,600	–	–	1.51%	17
2021 Q1	$1.45M	Hold	9,600	–	–	1.49%	23
2020 Q4	$1.45M	Hold	9,600	–	–	1.59%	16
2020 Q3	$1.3M	Hold	9,600	–	–	1.71%	15
2020 Q2	$1.31M	Buy	+9,600	New	+$1.22M	1.85%	14

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Capital Management Associates (New York)'s IBB Position: Q1 2026 in Review

Capital Management Associates (New York) held its iShares Biotechnology ETF (IBB) position steady in Q1 2026 at 4,000 shares worth $675K. The position accounts for 1.12% of the portfolio, ranked #34.

Capital Management Associates (New York) first reported a position in IBB in Q2 2020 and has held it in 9 quarters since. The position peaked at $1.57M in Q2 2021. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

Capital Management Associates (New York) held 4,000 shares of iShares Biotechnology ETF worth $675K as of Q1 2026.
Capital Management Associates (New York) left its iShares Biotechnology ETF share count unchanged in Q1 2026.
iShares Biotechnology ETF made up 1.12% of Capital Management Associates (New York)'s portfolio in Q1 2026, its #34 holding.
Capital Management Associates (New York) first reported a position in iShares Biotechnology ETF in Q2 2020 and has held it in 9 quarters since.
Capital Management Associates (New York)'s iShares Biotechnology ETF position peaked at $1.57M in Q2 2021.
917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Capital Management Associates (New York)'s 13F filing for Q1 2026, filed 4 May 2026.